AlzeCure Pharma (ALZCUR.ST) Stock Analysis & AI Equity Report
AlzeCure Pharma (ALZCUR.ST) overview
AlzeCure Pharma (ALZCUR.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, AlzeCure Pharma reported revenue of SEK 0m and operating profit of SEK -49.4m; the year-end share price was 2.00 SEK and market capitalisation was SEK 201m. AlzeCure Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AlzeCure Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About AlzeCure Pharma
AlzeCure Pharma is a Swedish pharmaceutical company developing small-molecule drug candidates for disorders of the central nervous system, with a focus on Alzheimer’s disease and pain. Its portfolio is organized around the NeuroRestore, Alzstatin and Painless platforms, covering symptomatic, disease-modifying and preventive programs in preclinical and clinical development.
Generate the AlzeCure Pharma report
AlzeCure Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for AlzeCure Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on AlzeCure Pharma
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.